Exploratory study of fecal microbiota transplantation combined with immune checkpoint inhibitors in the treatment of end-stage malig-nant tumor patients
10.12092/j.issn.1009-2501.2025.04.009
- VernacularTitle:肠菌移植联合免疫检查点抑制剂在终末期恶性肿瘤患者治疗中的探索性研究
- Author:
Yunqian CHU
1
;
Ya XUE
1
;
Hua JIANG
1
;
Chunjian QI
1
;
Hanjue DAI
1
;
Qingying XIAN
1
;
Wenyu ZHU
1
Author Information
1. 南京医科大学附属常州市第二人民医院肿瘤中心,常州 213100,江苏
- Publication Type:Journal Article
- Keywords:
fecal microbiota transplant;
immuno-therapy;
multi line treatment;
malignant tumor
- From:
Chinese Journal of Clinical Pharmacology and Therapeutics
2025;30(4):509-516
- CountryChina
- Language:Chinese
-
Abstract:
AIM:To explore the efficacy and safe-ty of fecal microbiota transplantation combined with immune checkpoint inhibitors(ICIs)for malig-nant tumor patients with failed multi line anti-tu-mor treatment and concomitant cachexia,and to explore the changes in blood immunity and intesti-nal microbial environment in patients.METHODS:Five patients with malignant tumors who failed multi line anti-tumor treatment were enrolled and treated with ICIs combined with fecal microbiota transplantation.The efficacy was evaluated every 2-3 cycles,and adverse reactions were observed.Fe-cal 16srRNA gene sequencing and serum immuno-logical indicators were dynamically detected.RE-SULTS:Except for one patient who died 2.5 months after transplantation due to excessive tumor bur-den at enrollment,the overall survival of the re-maining four patients were extended(7.4,8.3,28.5,52.3 months).One patient with multiple intra-cranial metastases of lung adenocarcinoma signifi-cantly reduced the intracranial metastasis after in-testinal microbiota transplantation and almost dis-appeared.The serum IL-2,IL-10,TGF-β and other indicators of patients increased rapidly and then slowly decreased with the increase of transplanta-tion time,and finally were higher than before trans-plantation,with statistical differences.16srRNA gene sequencing analysis revealed significant differ-ences in the overall distribution of gut microbiota in patients after transplantation,gradually ap-proaching healthy transplant donors.All patients did not experience grade 2 or above adverse reac-tions,and the safety was good.CONCLUSION:For patients with malignant tumors,the combination of fecal microbiota transplantation and immuno-therapy may improve their quality of life,serum im-mune environment,and intestinal microbiota com-position,have a positive impact on survival progno-sis,and are safe and controllable,opening up new treatment methods for end-stage patients.
